Navigation Links
FDA: 35 Innovative New Drugs Approved in Fiscal Year 2011
Date:11/3/2011

SILVER SPRING, Md., Nov. 3, 2011 /PRNewswire-USNewswire/ -- Over the past 12 months, the U.S. Food and Drug Administration approved 35 new medicines. This is among the highest number of approvals in the past decade, surpassed only by 2009 (37). Many of the drugs are important advances for patients, including: two new treatments for hepatitis C; a drug for late-stage prostate cancer; the first new drug for Hodgkin's lymphoma in 30 years; and the first new drug for lupus in 50 years. 

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

In a report released today, FY 2011 Innovative Drug Approvals, the FDA provided details of how it used expedited approval authorities, flexibility in clinical trial requirements and resources collected under the Prescription Drug User Fee Act (PDUFA) to boost the number of innovative drug approvals to 35 for the fiscal year (FY) ending Sept. 30, 2011.  The approvals come while drug safety standards have been maintained.

The report shows faster approval times in the United States when compared to the FDA's counterparts around the globe. Twenty-four of the 35 approvals occurred in the United States before any other country in the world and also before the European Union, continuing a trend of the United States leading the world in first approval of new medicines.  

"Thirty-five major drug approvals in one year represents a very strong performance, both by industry and by the FDA, and we continue to use every resource possible to get new treatments to patients," said Margaret Hamburg, M.D., Commissioner of Food and Drugs. "We are committed to working with industry to promote the science and innovation it takes to produce breakthrough treatments and to ensure that our nation is fully equipped to address the public health challenges of the 21st century."

Among the new drugs approved in FY 2011, a number are notable for their advances in patient care and for the efficiency with which they were approved:

  • Two of the drugs – one for melanoma and one for lung cancer – are breakthroughs in personalized medicine. Each was approved with a diagnostic test that helps identify patients for whom the drug is most likely to bring benefits;
  • Seven of the new medicines provide major advances in cancer treatment;
  • Almost half of the drugs were judged to be significant therapeutic advances over existing therapies for heart attack, stroke and kidney transplant rejection;
  • Ten are for rare or "orphan" diseases, which frequently lack any therapy because of the small number of patients with the condition, such as a treatment for hereditary angioedema;
  • Almost half (16) were approved under "priority review," in which the FDA has a six month goal to complete its review for safety and effectiveness;
  • Two-thirds of the new approvals were completed in a single review cycle, meaning sufficient evidence was provided by the manufacturer so that the FDA could move the application through the review process without requesting major new information;
  • Three were approved using "accelerated approval," a program under which the FDA approves safe and effective medically important new drugs quickly, and relies on subsequent post-market studies to confirm clinical benefit. For example, Corifact, the first treatment approved for a rare blood clotting disorder, was approved under this program; and
  • Thirty-four of 35 were approved on or before the review time targets agreed to with industry under PDUFA, including three cancer drugs that FDA approved in less than six months.

The Prescription Drug User Fee Act was established by Congress in 1992 to ensure that the FDA had the necessary resources for the safe and timely review of new drugs and for increased drug safety efforts. The current legislative authority for PDUFA expires on Sept. 30, 2012.  

"Before the PDUFA program, American patients waited for new drugs long after they were available elsewhere," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "As a result of the user fee program, new drugs are rapidly available to patients in the United States while maintaining our high standards for safety and efficacy."

In October 2011, the FDA released a new plan, Driving Biomedical Innovation: Initiatives to Improve Products for Patients, to assist companies engaged in new product development, particularly smaller, entrepreneurial companies.

In a separate action, the agency also released a report this week on drug shortages, expanded its current actions to address the problem, and, at the direction of the President, will broaden early notification of drug shortages and work with the Department of Justice to prevent price gouging.

For information:  

Report on FY 2011 Innovative Drug Approvals
http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm276385.htm

Driving Biomedical Innovation:  Initiatives to Improve Products for Patients
http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm274333.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference
4. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
7. Innovative Brain Scanning for Alzheimers Screening Unveiled
8. Gates Foundation Seeks Proposals for Innovative Global Health Research
9. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
10. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
11. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... InDex Pharmaceuticals Holding AB (publ) today announced ... of the European Crohn,s and Colitis Organisation (ECCO). The ECCO congress ... on inflammatory bowel disease (IBD). The congress is held in ... ... again having been selected to present data at the largest IBD ...
(Date:1/21/2017)... , Jan. 20, 2017 ResMed (NYSE: ... Medical ( Winter Haven, Florida ) today announced they ... parties. BMC and 3B will be permitted to sell their existing ... make a one-time settlement payment to 3B to close the ... did not include an admission of liability or wrongdoing by any ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... Trends - Technology, Route Of Administration, End User - Forecast to ... ... to grow at a CAGR of around 7.8% over the next ... This industry report analyzes the global markets for Advanced Drug Delivery ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... DMG Productions is proud to announce ... scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment will ... address the limitations of fatigue monitoring technologies within the mining industry. Today SmartCap ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... organization in North America for the scientific development, healthcare training and clinical application ... Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , ...
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... text with video footage. ProRandom works by using a virtual camera to create the ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/22/2017)... ... , ... Phytocéane invites clients to take an exotic journey deep into the ... MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the coast ... coral to create this gentle, velvety body cream to envelop the skin in moisture ...
Breaking Medicine News(10 mins):